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older adults Methods: Medicare beneficiaries participated in the 2007 HRS pre-
scription drug survey and 2009 HRS well-being survey and enrolled in Medicare part 
D (stand-alone), HMO, fee-for service or Advantage plans. The study sample includes 
773 individuals with at least one of four common chronic health conditions and 
responded both years. Random intercept logit model was estimated for medica-
tion non-adherence and population based generalized estimating equation was 
utilized to examine poverty-adjusted well-being (excluding out-of-pocket medical 
expenditure from poverty threshold) Results: Preliminary results indicate that 
individuals having inertia in plan switching were 3.4 times more likely to be non-
adherent to regular prescription medications compared to those without inertia 
(odds ratio estimate, 3.4 with p< 0.001). Neither switching from brand name drug to 
generic drug plan nor plan level switching appeared to be a significant predictor of 
medication non-adherence or economic well-being in this group. ConClusions: 
Consumer inertia rather switching decision appears to be a significant factor influ-
encing medication non-adherence among individuals with four common chronic 
health conditions
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objeCtives: The aim of this study was to evaluate adherence of family doctors to 
National Clinical Practice Guideline (2012) in the management of hypertension with 
co-morbidities in Ukraine. Methods: Cross-sectional study was done at a primary 
care network in Ukraine. Total 62 physicians and 1550 patients’ prescriptions written 
by same physicians (25 prescriptions per physician) were analyzed. All patients had 
hypertension with co-morbidities. Depending on the recommendations of National 
Clinical Practice Guideline (2012), the prescriptions were clustered as compliant and 
non-compliant prescriptions. All obtained data were analyzed using descriptive 
and inferential statistics. Results: A statistically significant negative association 
(r= -0.089, p= 0.005) was observed between hypertension control and co-morbidities. 
Compliant patients had statistically weak negative association (r= -0.078, p= 0.015) 
with patients having co-morbidities (38.2%). No statistically significant association 
was observed between guideline adherence and any other co-morbidity. Majority 
of the patients received guidelines-compliant pharmacotherapy. The overall good 
level of physician compliance with National Clinical Practice Guideline (2012) was 
observed in the management of hypertension with co-morbidities. ConClusions: 
The study explored several features of prescription pattern of the primary care 
physicians involved in the management of hypertension with co-morbidities and 
recognized the need for improvement in their prescription pattern for treating the 
hypertension.
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objeCtives: EQ-5D and SF-6D can both be used to derive health utility scores. 
Variations in utility scores can have a major impact on the results of cost-util-
ity studies. This study aimed to compare the health utility of acute coronary 
syndrome (ACS) patients from Malaysia measured by the two descriptive sys-
tems Methods: Data was obtained from an earlier study. The study collected data 
from ACS patients admitted to the Sarawak General Hospital who consented to 
the study. Validated language versions of the EQ-5D-3L and SF-36v1 were admin-
istered during admission and 12-months post-admission. Health utility scores 
were calculated using the Malaysian EQ-5D-3L utility tariff and Brazier SF-6D 
algorithm. Patient demographic and clinical data were extracted from medi-
cal records. Results: Data from 100 of 112 subjects were usable for analysis. 
Mean age of patients was 56.3 years and 88% were male. Utility scores meas-
ured by EQ-5D were higher than those measured by SF-6D. Mean utility scores 
from EQ-5D and SF-6D during admission were 0.75 and 0.56 (p< 0.0001); and 0.82 
and 0.79 (p= 0.0521) 12 months post-admission, respectively. Improvement in 
utility scores from baseline to 12 months was statistically significant for both 
EQ-5D (0.06, p= 0.0300) and SF-6D (0.23, p< 0.001). EQ-5D and SF-6D utilities were 
moderately correlated at 12 months (r= 0.68, p< 0.0001) but not during admission 
(r= 0.12, p= 0.2183). Ceiling effect was observed in EQ-5D utility scores, whereby 
22% and 29% of patients reported the best possible EQ-5D health state during 
admission and 12 months, respectively. Only 3% recorded the highest SF-6D utility 
at 12 months. ConClusions: Consistent with past studies, utility scores of ACS 
patients calculated by EQ-5D (Malaysian value set) and SF-6D (Brazier algorithm) 
resulted in different utility values, magnitude of change and extent of ceiling 
effect. Properties of patient reported outcome instruments should also be consid-
ered when selection utility measures for cost-effectiveness studies.
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objeCtives: With a lack of an essential evidence on utilities to support cost-effec-
tiveness analysis of hypertension management in Vietnam, we aimed to gather 
data on health utilities for hypertensive patients and identify predictors of util-
ity. Methods: Hypertensive patients, from 40 to 80 years old visiting the hospital 
were invited to take a survey. Short-form 36 version 2 translated into Vietnamese 
was used to interview patients. We applied a specific published model to measure 
utilities, that explains a reasonable share of variance, especially in those cases when 
only relatively small differences in health are expected. Results: 712 patients were 
included in the study. Mean utility of these patients was 0.72 +/- 0.14. Controlling 
and pharmacy/IV therapy services ($9,484). Average cost per patient in all cat-
egories at 1-year post-AIS increased significantly from the pre-admission period. 
Diagnostic/lab services expenditures increased $20,225; pharmacy/IV therapy 
services increased $6,864; and outpatient visits increased $2,484; all p-values < 
0.001. Compared to the overall AIS patients, the early readmitted patients expe-
rienced higher resource utilization and expenditures. ConClusions: Economic 
burden of Medicare AIS patients is substantial. Resource utilization and direct 
costs were highest during the first 30 days of AIS hospitalization and doubles in 
the first year. Costs significantly increased in the year following stroke compared 
to the pre-admission year.
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objeCtives: This study quantified the total direct healthcare costs of aortic and 
mitral valvular disease to insurers and patients, stratified by asymptomatic and 
symptomatic disease status. Methods: Using 1996-2011 data from the Medical 
Expenditure Panel Survey (MEPS), a large, nationally-representative database from 
the US, this study performed descriptive analyses of the total annual healthcare 
costs to insurers and patients for aortic and mitral valve disease. The healthcare 
costs were reported at the individual and US aggregate levels. Individuals with aortic 
and mitral valve disease were identified by International Classification of Disease 
Codes, 9threvision and stratified as either symptomatic or asymptomatic based on 
the presence of comorbid conditions. Results: The MEPS database included 148 
patients with aortic disease and 1,057 with mitral valve disease. Asymptomatic 
patients comprised 64% and 70% of the population for aortic disease and mitral 
valve disease, respectively. Symptomatic aortic disease patients incurred higher 
overall annual healthcare direct costs per patient compared to asymptomatic 
patients ($30,146 vs. $16,065). Symptomatic mitral valve disease patients incurred 
greater annual healthcare costs per patient compared to asymptomatic patients 
($14,054 vs. $7,198). Because these were direct costs, the majority of the health-
care expenditures were borne by the insurer (range 79% to 90% based on type of 
disease and symptom status) rather than the patient. When aggregated to the US 
population, the overall annual direct cost was $4.5 billion and $10 billion for aortic 
disease and mitral valve disease, respectively. Approximately 75% and 52% of the 
total annual direct cost was attributed to symptomatic aortic valve and mitral valve 
disease patients, respectively. ConClusions: These findings indicate that the total 
direct healthcare costs of valvular disease are quite large. Symptomatic patients 
incur disproportionately greater healthcare costs, possibly due to costly surgical 
interventions required to treat their valvular disease.
CardioVasCUlar disorders – Patient-reported outcomes & Patient  
Preference studies
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objeCtives: Among individuals suffering from chronic kidney disease (CKD) newly 
treated with lipid-lowering drugs (LLD): (1) to estimate persistence with LLD one 
year after treatment initiation; (2) among those persisting, to estimate compliance 
in the year following LLD initiation; (3) to identify factors associated with persis-
tence and with compliance. Methods: Using Quebec administrative databases we 
carried out a cohort study of individuals aged ≥ 18 who had started a LLD between 
January 1, 2000 and December 31, 2011. Individuals still undergoing treatment with 
any LLD one year after their first claim were considered persistent. Of these, we 
considered compliant those with a supply of drugs for ≥ 80% of days. We identified 
factors associated with persistence and with compliance using modified Poisson 
regression. Results: Among 14,607 eligible individuals, 80.7% were persistent and 
88.7% of these were compliant with their LLD. Individuals with low (Prevalence ratio: 
1.03; 95%IC: 1.01-1.06) and medium socioeconomic status (SES) (1.04; 1.02-1.05) com-
pared with those with high SES, treated by a nephrologist (vs. general practitioner) 
(1.06; 1.04-1.09), who had hypertension (1.04; 1.02-1.06), diabetes (1.04; 1.03-1.06), 
stroke (1.09; 1.07-1.12) or coronary disease (1.07; 1.05-1.09) were more likely to be 
persistent. Individuals more likely to be compliant were aged ≥ 66 (vs. 18-65) (1.04; 
1.01-1.07), had low (vs. high) SES (1.08; 1.06-1.10), and had ≥ 12 (vs. < 7) distinct drugs 
(1.03; 1.0-1.05), had been hospitalized (1.04; 1.02-1.06) or had stroke (1.04; 1.03-1.06) 
in the year prior to LLD treatment initiation. ConClusions: One year after LLD 
initiation, 28% of individuals with CKD were either no longer taking their treatment 
or had not been compliant to it. Results could help target individuals who need help 
to better manage their LLD treatment.
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objeCtives: It is not well understood the relative impacts of switching (from brand 
name drug to generic drug or plan switching) and consumer inertia on medication 
non-adherence and economic well-being for individuals with at least four most 
common chronic conditions: diabetes, hypertension, heart disease and psychiatric 
problem. The goal of the current study is to examine the whether switching decision 
or consumer inertia impact medication adherence and/or economic well-being of 
